Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant palbociclib + letrozole + trastuzumab/pertuzumab versus paclitaxel + trastuzumab/pertuzumab in ER-positive/HER2-positive early breast cancer
2017-005067-40Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Palbociclib + letrozole + trastuzumab + pertuzumab with Paclitaxel + trastuzumab + pertuzumab (2 arms). Primary endpoint: Pathological complete response. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-005067-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005067-40.